Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Dicerna Pharmaceuticals Inc (DRNA) A Good Stock To Buy?

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback the hedge funds employing these talents and can benefit from their vast resources and knowledge in that way. We analyze quarterly 13F filings of nearly 750 hedge funds and, by looking at the smart money sentiment that surrounds a stock, we can determine whether it has the potential to beat the market over the long-term. Therefore, let’s take a closer look at what smart money thinks about Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).

Is Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) a bargain? Investors who are in the know are in a pessimistic mood. The number of bullish hedge fund bets went down by 3 in recent months. Our calculations also showed that DRNA isn’t among the 30 most popular stocks among hedge funds (see the video below). DRNA was in 16 hedge funds’ portfolios at the end of the second quarter of 2019. There were 19 hedge funds in our database with DRNA holdings at the end of the previous quarter.
5 Most Popular Stocks Among Hedge Funds
Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ large-cap stock picks indeed failed to beat the market between 1999 and 2016. However, we were able to identify in advance a select group of hedge fund holdings that outperformed the market by 40 percentage points since May 2014 through May 30, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that’ll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 25.7% through September 30, 2019. That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

Roberto-Mignone1

Unlike former hedge manager, Dr. Steve Sjuggerud, who is convinced Dow will soar past 40000, our long-short investment strategy doesn’t rely on bull markets to deliver double digit returns. We only rely on hedge fund buy/sell signals. Let’s take a look at the fresh hedge fund action surrounding Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).

What have hedge funds been doing with Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)?

Heading into the third quarter of 2019, a total of 16 of the hedge funds tracked by Insider Monkey were long this stock, a change of -16% from the first quarter of 2019. By comparison, 16 hedge funds held shares or bullish call options in DRNA a year ago. So, let’s review which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

DRNA_oct2019

According to Insider Monkey’s hedge fund database, Roberto Mignone’s Bridger Management has the biggest position in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), worth close to $65.7 million, corresponding to 5.2% of its total 13F portfolio. The second largest stake is held by EcoR1 Capital, led by Oleg Nodelman, holding a $52.2 million position; 5.3% of its 13F portfolio is allocated to the company. Some other peers that hold long positions encompass Phill Gross and Robert Atchinson’s Adage Capital Management, Peter Kolchinsky’s RA Capital Management and Ken Griffin’s Citadel Investment Group.

Because Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has experienced bearish sentiment from the aggregate hedge fund industry, it’s safe to say that there was a specific group of money managers who sold off their full holdings last quarter. It’s worth mentioning that Steve Cohen’s Point72 Asset Management dumped the biggest stake of all the hedgies watched by Insider Monkey, comprising about $19.8 million in stock, and Paul Marshall and Ian Wace’s Marshall Wace LLP was right behind this move, as the fund dropped about $3 million worth. These moves are interesting, as aggregate hedge fund interest fell by 3 funds last quarter.

Let’s now take a look at hedge fund activity in other stocks – not necessarily in the same industry as Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) but similarly valued. These stocks are Schweitzer-Mauduit International, Inc. (NYSE:SWM), Milacron Holdings Corp (NYSE:MCRN), SecureWorks Corp. (NASDAQ:SCWX), and H&E Equipment Services, Inc. (NASDAQ:HEES). This group of stocks’ market caps are similar to DRNA’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
SWM 10 24291 0
MCRN 13 60802 -11
SCWX 9 19866 -3
HEES 12 37700 -1
Average 11 35665 -3.75

View table here if you experience formatting issues.

As you can see these stocks had an average of 11 hedge funds with bullish positions and the average amount invested in these stocks was $36 million. That figure was $290 million in DRNA’s case. Milacron Holdings Corp (NYSE:MCRN) is the most popular stock in this table. On the other hand SecureWorks Corp. (NASDAQ:SCWX) is the least popular one with only 9 bullish hedge fund positions. Compared to these stocks Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is more popular among hedge funds. Our calculations showed that top 20 most popular stocks among hedge funds returned 24.4% in 2019 through September 30th and outperformed the S&P 500 ETF (SPY) by 4 percentage points. Unfortunately DRNA wasn’t nearly as popular as these 20 stocks and hedge funds that were betting on DRNA were disappointed as the stock returned -8.8% during the third quarter and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as many of these stocks already outperformed the market in Q3.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.